SNY's Subcutaneous Sarclisa Outperforms IV Formulation in Cancer Study

Sanofi (SNY) announced that the phase III IRAKLIA study, which evaluated a fixed-dose subcutaneous (SC) formulation of its blood cancer drug, Sarclisa (isatuximab) for the treatment of relapsed or refractory multiple myeloma (R/R MM) has met the co-primary endpoints.Data from the study showed that the new SC formulation of Sarclisa in combination with Bristol Myers’ (BMY) Pomalyst (pomalidomide) and dexamethasone (Pd) when administered through an on-body delivery system (OBDS) demonstrated non-inferiority i ...